The FDA's designation for skin and skin structure infections—acute bacterial skin and skin structure infections, or ABSSSI—includes the following criteria: accompanied by redness, edema, and/or induration of a minimum surface area of 75 cm2, accompanied by lymph node enlargement or systemic symptoms such as fever ≥38°C (100.4°F)3:
TEFLARO® clinical trials evaluated patients with lesions size >75 square centimeters and having one of the following infection types: major abscess with >5 cm of surrounding erythema, wound infection, or deep/extensive cellulitis.
Proven Clinical Activity in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) When Caused by the Following Pathogens: | |
Gram-positive organisms | Gram-negative organisms |
Methicillin-susceptible Staphylococcus aureus (MSSA) | Escherichia coli |
Methicillin-resistant S. aureus (MRSA) | Klebsiella pneumoniae |
Streptococcus pyogenes | Klebsiella oxytoca |
Streptococcus agalactiae |
Proven Clinical Activity in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) When Caused by the Following Pathogens: |
Gram-positive organisms |
Methicillin-susceptible Staphylococcus aureus (MSSA) |
Methicillin-resistant S. aureus (MRSA) |
Streptococcus pyogenes |
Streptococcus agalactiae |
Gram-negative organisms |
Escherichia coli |
Klebsiella pneumoniae |
Klebsiella oxytoca |
TEFLARO was studied in 1396 adults with complicated skin and skin structure infections
SEE THE STUDYThese hypothetical case studies present examples of types of patients who may benefit from TEFLARO.
Please also see full Prescribing Information.
Please also see full Prescribing Information.